Ind-Swift Laboratories Limited

Informe acción NSEI:INDSWFTLAB

Capitalización de mercado: ₹6.1b

Ind-Swift Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Ind-Swift Laboratories ha aumentado sus beneficios a una tasa media anual de 84.4%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 13.3% anual. Los ingresos han ido creciendo a una tasa media de 7.4% al año. La rentabilidad financiera de Ind-Swift Laboratories es de 36.9%, y sus márgenes netos son de 50.3%.

Información clave

84.4%

Tasa de crecimiento de los beneficios

84.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals 17.5%
Tasa de crecimiento de los ingresos7.4%
Rentabilidad financiera36.9%
Margen neto50.3%
Próxima actualización de resultados14 Feb 2025

Actualizaciones de resultados anteriores recientes

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Nov 20
There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

May 21
Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

Recent updates

There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Nov 20
There Are Some Reasons To Suggest That Ind-Swift Laboratories' (NSE:INDSWFTLAB) Earnings Are A Poor Reflection Of Profitability

Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Oct 20
Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

Jul 02
Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company

Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

May 21
Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story

Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Apr 13
Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

Dec 28
Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Jul 22
These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well

Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Jul 12
Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet

Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

Feb 17
Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?

We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

Dec 30
We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings

These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Nov 11
These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively

Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Jun 27
Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?

Desglose de ingresos y gastos

Cómo gana y gasta dinero Ind-Swift Laboratories. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NSEI:INDSWFTLAB Ingresos, gastos y beneficios (INR Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 247,4233,7349360
30 Jun 2410,0374,0471,1990
31 Mar 2412,9734,2101,5820
31 Dec 2312,0044321,5340
30 Sep 2312,2565131,4950
30 Jun 2312,3754501,4100
31 Mar 2312,1594761,4010
31 Dec 2212,2311131,2790
30 Sep 2211,571-21,2340
30 Jun 2210,691-111,1640
31 Mar 2210,529-211,2780
31 Dec 219,7543011,1630
30 Sep 219,5552561,1440
30 Jun 219,5361111,1300
31 Mar 219,068-311,0790
31 Dec 208,7762771,0970
30 Sep 208,536771,0820
30 Jun 208,360-1111,0220
31 Mar 207,993-2121,0580
31 Dec 197,977-7341,0210
30 Sep 197,992-2111,0120
30 Jun 197,872-359290
31 Mar 197,7902891,0180
31 Mar 187,7692209630
31 Mar 177,142-3917650
31 Mar 166,641-5876940
31 Mar 156,778-1,1945710
31 Mar 149,738-1,22086778

Ingresos de calidad: INDSWFTLAB tiene un alto nivel de ganancias no monetarias.

Margen de beneficios creciente: Los actuales márgenes de beneficio (50.3%) de INDSWFTLAB son superiores a los del año pasado (4.2%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: INDSWFTLAB ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 84.4% al año.

Acelerando crecimiento: El crecimiento de los beneficios de INDSWFTLAB en el último año (628.3%) supera su media de 5 años (84.4% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de INDSWFTLAB en el último año (628.3%) superó al de la industria Pharmaceuticals 20.5%.


Rentabilidad financiera

Alta ROE: La rentabilidad financiera (36.9%) de INDSWFTLAB se considera alta.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado